The EDGE

A window into immunoglobulin quantitation and plasma cell disease: antigen epitopes defined by the junction of immunoglobulin heavy and light chains

J A Katzmann and S V Rajkumar

Leukemia 2013 27: 1-2; 10.1038/leu.2012.201

Leading Article

A record-based case–control study of natural background radiation and the incidence of childhood leukaemia and other cancers in Great Britain during 1980–2006

G M Kendall, M P Little, R Wakeford, K J Bunch, J C H Miles, T J Vincent, J R Meara and M F G Murphy

Leukemia 2013 27: 3-9; advance online publication, June 5, 2012; 10.1038/leu.2012.151

Spotlight Reviews

SPOTLIGHT ON EPIGENETICS AND HEMATOLOGIC MALIGNANCIES

The ASXL–BAP1 axis: new factors in myelopoiesis, cancer and epigenetics

O Abdel-Wahab and A Dey

Leukemia 2013 27: 10-15; advance online publication, October 9, 2012; 10.1038/leu.2012.288

SPOTLIGHT ON MIRNA AND HEMATOPOIESIS

The hunting of targets: challenge in miRNA research

F Akbari Moqadam, R Pieters and M L den Boer

Leukemia 2013 27: 16-23; advance online publication, July 3, 2012; 10.1038/leu.2012.179

SPOTLIGHT ON PERSPECTIVE ON STEM CELL HOMING AND MOBILIZATION

Hematopoietic stem cell mobilization: updated conceptual renditions

H Bonig and T Papayannopoulou

Leukemia 2013 27: 24-31; advance online publication, September 6, 2012; 10.1038/leu.2012.254

Original Articles

MOLECULAR TARGETS FOR THERAPY

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities

M Ren, H Qin, R Ren and J K Cowell

Leukemia 2013 27: 32-40; advance online publication, July 11, 2012; 10.1038/leu.2012.188

ACUTE LEUKEMIAS

Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial

S Jenkinson, K Koo, M R Mansour, N Goulden, A Vora, C Mitchell, R Wade, S Richards, J Hancock, A V Moorman, D C Linch and R E Gale

Leukemia 2013 27: 41-47; advance online publication, July 3, 2012; 10.1038/leu.2012.176

Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors

A B Williams, B Nguyen, L Li, P Brown, M Levis, D Leahy and D Small

Leukemia 2013 27: 48-55; advance online publication, July 13, 2012; 10.1038/leu.2012.191

EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia

M Konantz, M C André, M Ebinger, M Grauer, H Wang, S Grzywna, O C Rothfuss, S Lehle, O S Kustikova, H R Salih, R Handgretinger, F Fend, C Baum, L Kanz, L Quintanilla-Martinez, K Schulze-Osthoff, F Essmann and C Lengerke

Leukemia 2013 27: 56-65; advance online publication, July 25, 2012; 10.1038/leu.2012.211

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells Open

J Etchin, Q Sun, A Kentsis, A Farmer, Z C Zhang, T Sanda, M R Mansour, C Barcelo, D McCauley, M Kauffman, S Shacham, A L Christie, A L Kung, S J Rodig, Y M Chook and A T Look

Leukemia 2013 27: 66-74; advance online publication, July 31, 2012; 10.1038/leu.2012.219

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

A K Burnett, R K Hills, A E Hunter, D Milligan, W J Kell, K Wheatley, J Yin, M F McMullin, H Dignum, D Bowen and N H Russell on behalf of the UK National Cancer Research Institute AML Working Group

Leukemia 2013 27: 75-81; advance online publication, August 14, 2012; 10.1038/leu.2012.229

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

S Schnittger, C Eder, S Jeromin, T Alpermann, A Fasan, V Grossmann, A Kohlmann, T Illig, N Klopp, H-E Wichmann, K-A Kreuzer, C Schmid, P Staib, R Peceny, N Schmitz, W Kern, C Haferlach and T Haferlach

Leukemia 2013 27: 82-91; advance online publication, September 11, 2012; 10.1038/leu.2012.262

Immunoglobulin gamma heavy chain gene with somatic hypermutation is frequently expressed in acute myeloid leukemia

X Qiu, X Sun, Z He, J Huang, F Hu, L Chen, P Lin, M J You, L J Medeiros and C C Yin

Leukemia 2013 27: 92-99; advance online publication, July 9, 2012; 10.1038/leu.2012.184

The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML

S M Sun, V Rockova, L Bullinger, M K Dijkstra, H Döhner, B Löwenberg and M Jongen-Lavrencic

Leukemia 2013 27: 100-106; advance online publication, June 13, 2012; 10.1038/leu.2012.158

CHRONIC MYELOPROLIFERATIVE NEOPLASIAS

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

F J Giles, P D le Coutre, J Pinilla-Ibarz, R A Larson, N Gattermann, O G Ottmann, A Hochhaus, J P Radich, G Saglio, T P Hughes, G Martinelli, D-W Kim, S Novick, K Gillis, X Fan, J Cortes, M Baccarani and H M Kantarjian

Leukemia 2013 27: 107-112; advance online publication, July 5, 2012; 10.1038/leu.2012.181

MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia

F J Giles, R T Swords, A Nagler, A Hochhaus, O G Ottmann, D A Rizzieri, M Talpaz, J Clark, P Watson, A Xiao, B Zhao, D Bergstrom, P D Le Coutre, S J Freedman and J E Cortes

Leukemia 2013 27: 113-117; advance online publication, July 9, 2012; 10.1038/leu.2012.186

Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors

F U Wöhrle, S Halbach, K Aumann, S Schwemmers, S Braun, P Auberger, D Schramek, J M Penninger, S Laßmann, M Werner, C F Waller, H L Pahl, R Zeiser, R J Daly and T Brummer

Leukemia 2013 27: 118-129; advance online publication, August 3, 2012; 10.1038/leu.2012.222

SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function Open

N Hansen, H Ågerstam, M Wahlestedt, N Landberg, M Askmyr, M Ehinger, M Rissler, H Lilljebjörn, P Johnels, J Ishiko, J V Melo, W S Alexander, D Bryder, M Järås and T Fioretos

Leukemia 2013 27: 130-135; advance online publication, June 22, 2012; 10.1038/leu.2012.169

CHRONIC LYMPHOCYTIC LEUKEMIA

Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls

J Moreira, K G Rabe, J R Cerhan, N E Kay, J W Wilson, T G Call, J F Leis, D F Jelinek, S M Schwager, D A Bowen, C A Hanson, S L Slager and T D Shanafelt

Leukemia 2013 27: 136-141; advance online publication, July 11, 2012; 10.1038/leu.2012.187

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL

A C Rawstron, S Böttcher, R Letestu, N Villamor, C Fazi, H Kartsios, R M de Tute, J Shingles, M Ritgen, C Moreno, K Lin, A R Pettitt, M Kneba, E Montserrat, F Cymbalista, M Hallek, P Hillmen and P Ghia on behalf of the European Research Initiative in CLL (ERIC)

Leukemia 2013 27: 142-149; advance online publication, July 31, 2012; 10.1038/leu.2012.216

450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments

N Cahill, A-C Bergh, M Kanduri, H Göransson-Kultima, L Mansouri, A Isaksson, F Ryan, K E Smedby, G Juliusson, C Sundström, A Rosén and R Rosenquist

Leukemia 2013 27: 150-158; advance online publication, August 27, 2012; 10.1038/leu.2012.245

STEM CELLS

Ex vivo expansion of normal and chronic myeloid leukemic stem cells without functional alteration using a NUP98HOXA10homeodomain fusion gene Open

I Sloma, S Imren, P A Beer, Y Zhao, V Lecault, D Leung, K Raghuram, C Brimacombe, K Lambie, J Piret, C Hansen, R K Humphries and C J Eaves

Leukemia 2013 27: 159-169; advance online publication, July 16, 2012; 10.1038/leu.2012.196

IMMUNOLOGY

Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function

D J DiLillo, J B Weinberg, A Yoshizaki, M Horikawa, J M Bryant, Y Iwata, T Matsushita, K M Matta, Y Chen, G M Venturi, G Russo, J P Gockerman, J O Moore, L F Diehl, A D Volkheimer, D R Friedman, M C Lanasa, R P Hall and T F Tedder

Leukemia 2013 27: 170-182; advance online publication, July 13, 2012; 10.1038/leu.2012.165

LYMPHOMA

IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas

N Gachard, M Parrens, I Soubeyran, B Petit, A Marfak, D Rizzo, M Devesa, M Delage-Corre, V Coste, M P Laforêt, A de Mascarel, J P Merlio, K Bouabdhalla, N Milpied, P Soubeyran, A Schmitt, D Bordessoule, M Cogné and J Feuillard

Leukemia 2013 27: 183-189; advance online publication, September 4, 2012; 10.1038/leu.2012.257

The novel tribody [(CD20)₂xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells

P Glorius, A Baerenwaldt, C Kellner, M Staudinger, M Dechant, M Stauch, F J Beurskens, P W H I Parren, J G J van de Winkel, T Valerius, A Humpe, R Repp, M Gramatzki, F Nimmerjahn and M Peipp

Leukemia 2013 27: 190-201; advance online publication, June 4, 2012; 10.1038/leu.2012.150

MYELOMA

Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients Open

A Bradwell, S Harding, N Fourrier, C Mathiot, M Attal, P Moreau, J-L Harousseau and H Avet-Loiseau

Leukemia 2013 27: 202-207; advance online publication, June 13, 2012; 10.1038/leu.2012.159

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS

J A Katzmann, R Clark, R A Kyle, D R Larson, T M Therneau, L J Melton, III, J T Benson, C L Colby, A Dispenzieri, O Landgren, S Kumar, A R Bradwell, J R Cerhan and S V Rajkumar

Leukemia 2013 27: 208-212; advance online publication, July 11, 2012; 10.1038/leu.2012.189

Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients Open

H Ludwig, D Milosavljevic, N Zojer, J M Faint, A R Bradwell, W Hübl and S J Harding

Leukemia 2013 27: 213-219; advance online publication, July 17, 2012; 10.1038/leu.2012.197

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

T E Witzig, K M Laumann, M Q Lacy, S R Hayman, A Dispenzieri, S Kumar, C B Reeder, V Roy, J A Lust, M A Gertz, P R Greipp, H Hassoun, S J Mandrekar and S V Rajkumar

Leukemia 2013 27: 220-225; advance online publication, August 20, 2012; 10.1038/leu.2012.236

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

S Z Usmani, J Crowley, A Hoering, A Mitchell, S Waheed, B Nair, Y AlSayed, F vanRhee and B Barlogie

Leukemia 2013 27: 226-232; advance online publication, June 18, 2012; 10.1038/leu.2012.160

Letters to the Editor

Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin Open

M Kurimoto, H Matsuoka, N Hanaoka, S Uneda, T Murayama, T Sonoki and H Nakakuma

Leukemia 2013 27: 233-235; advance online publication, July 3, 2012; 10.1038/leu.2012.178

HOX genes regulate Rac1 activity in hematopoietic cells through control of Vav2 expression

C Breitinger, E Maethner, M-P Garcia-Cuellar, A Schambony, K D Fischer, K Schilling and R K Slany

Leukemia 2013 27: 236-238; advance online publication, June 20, 2012; 10.1038/leu.2012.166

Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report

F Ostronoff, M Othus, P A Ho, M Kutny, D E Geraghty, S H Petersdorf, J E Godwin, C L Willman, J P Radich, F R Appelbaum, D L Stirewalt and S Meshinchi

Leukemia 2013 27: 238-241; advance online publication, June 22, 2012; 10.1038/leu.2012.168

Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins

N J Weston-Bell, D Hendriks, G Sugiyarto, N A Bos, H C Kluin-Nelemans, F Forconi and S S Sahota

Leukemia 2013 27: 241-245; advance online publication, June 18, 2012; 10.1038/leu.2012.163

A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98–NSD1 fusion gene

A Fasan, C Haferlach, T Alpermann, W Kern, T Haferlach and S Schnittger

Leukemia 2013 27: 245-248; advance online publication, August 14, 2012; 10.1038/leu.2012.230

Loss of chromosomes is the primary event in near-haploid and low-hypodiploid acute lymphoblastic leukemia

S Safavi, E Forestier, I Golovleva, G Barbany, K H Nord, A V Moorman, C J Harrison, B Johansson and K Paulsson

Leukemia 2013 27: 248-251; advance online publication, August 14, 2012; 10.1038/leu.2012.227

BTG1 deletions do not predict outcome in Down syndrome acute lymphoblastic leukemia

T D Buitenkamp, R Pieters, M Zimmermann, V de Haas, S M Richards, A J Vora, C D Mitchell, C Schwab, C J Harrison, A V Moorman, M M van den Heuvel-Eibrink and C M Zwaan

Leukemia 2013 27: 251-252; advance online publication, July 17, 2012; 10.1038/leu.2012.199

Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma

H Tilly, F Morschhauser, G Salles, R-O Casasnovas, P Feugier, T J Molina, F Jardin, L Terriou, C Haioun and B Coiffier

Leukemia 2013 27: 252-255; advance online publication, June 26, 2012; 10.1038/leu.2012.172

Risk of developing chronic lymphocytic leukemia is influenced by HLA-A class I variation

M C Di Bernardo, P Broderick, S Harris, M J S Dyer, E Matutes, C Dearden, D Catovsky and R S Houlston

Leukemia 2013 27: 255-258; advance online publication, July 2, 2012; 10.1038/leu.2012.173